Ideagen teams up with World Health Organisation
Francesca Morgan
RNS Newswire
14:06, 22nd May 2020

Ideagen (AIM:IDEA FOLLOW) has partnered with the World Health Organisation in support of its collaboration and policy making work during the coronavirus pandemic.

The group’s document collaboration and governance software product, PleaseReview, enabled the WHO to conduct its first-ever digital World Health Assembly this week.

PleaseReview allows for real-time collaboration on documents, offers a secure means of capturing comments and provides a full audit trail of responses, changes and agreements. 

“We are delighted to support the WHO in their life saving work, especially at such a crucial period,” said Ben Dorks, CEO of information management software supplier, Ideagen.

The group said PleaseReview has provided the WHO with a solution to their problems and is of  ‘paramount importance’ to the WHO given the global significance of its debates.

Shares in Ideagen were trading 5.48% higher at 183p on Friday afternoon.

 

The 73rd World Health Assembly took place earlier this week with delegates adopting a landmark resolution to bring the world together to fight the COVID-19 pandemic.

The software allowed WHO to invite member states to conduct a first review of policy documents that would normally be conducted face to face, in a secure, online environment. 

The assembly was its first-ever to be held virtually and only had two items up for discussion with the main one being the pandemic and the global response to it, the group detailed.

“The scale of the challenge facing them is enormous and we are extremely proud that we can offer them the use of PleaseReview, a product that will make that challenge a little easier to handle,” added Dorks.

Follow News & Updates from Ideagen here:FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist